Tag: Biotech and Pharma

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company’s cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine.

Eli Lilly (LLY)+1.55% stock was falling early Thursday even as the drugmaker posted first-quarter earnings above analysts’ expectations, driven by higher sales of its blockbuster weight-loss drugs Zepbound and Mounjaro.

The U.S. Food and Drug Administration has approved Johnson & Johnson’s (JNJ.N),  drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.

Hims & Hers stock HIMS+1.39% jumped after the telehealth company that has built a business around selling copycat weight-loss drugs announced a deal with Ozempic-maker Novo Nordisk.

Pfizer PFE +0.57% reported earnings that beat Wall Street expectations early Tuesday, but said it is “unable to predict” tariff-related impacts “at this time.”

Merck KGaA (MRCG.DE),  has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O),  for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

AbbVie (ABBV +3.15%) gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its financial forecasts for the year.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its latest financial results late Thursday should reinforce its position

Οι επενδύσεις μας αποδίδουν και ενισχύουν σημαντικά την κερδοφορία μας. Μετά από 18 χρόνια ανταμείβουμε τους μετόχους για την εμπιστοσύνη τους, διανέμοντας μέρισμα (2 λεπτά/ανά μετοχή)», δήλωσε ο CFO του ομίλου.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market.

Bristol Myers Squibb’s Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the U.S. over the next five years, amid concerns about the impact of possible new White House tariffs on pharma goods from abroad.

Eli Lilly (LLY.N),  said on Thursday its experimental pill, orforglipron, led to weight loss of nearly 8% at the highest dose and lowered blood sugar in patients with type 2 diabetes in a late-stage trial.

Abbott Laboratories ABT-0.90% declined slightly in premarket trading Wednesday after the healthcare company posted first-quarter sales that missed Wall Street expectations.

J&J beat quarterly profit and revenue expectations and raised its dividend but didn’t change its profit outlook, and the stock pulled back.

Οι εφαρμογές θα εστιάζουν στη διαχείριση του πόνου με βάση τις εγκεκριμένες ενδείξεις των αντίστοιχων φαρμάκων, συμπεριλαμβανομένων των τελικών προϊόντων φαρμακευτικής κάνναβης . 

Pfizer stock fell after suffering a setback developing a new weight-loss drug.

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson’s (JNJ.N), opens new tab $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company’s bankruptcy strategy has failed in court.

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. 

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.